<DOC>
	<DOCNO>NCT00003003</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Some cancer become resistant chemotherapy drug . Combining mitomycin chemotherapy drug may reduce resistance drug allow cancer cell kill . PURPOSE : Phase I trial study effectiveness mitomycin mitoxantrone treat patient acute myelogenous leukemia determine whether mitomycin reduce cancer 's resistance chemotherapy .</brief_summary>
	<brief_title>Mitomycin Mitoxantrone Treating Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether single mitomycin C treatment suppress expression one proteins associate multidrug resistance phenotype leukemia cell patient refractory acute myelogenous leukemia . II . Determine maximum tolerate dose combination mitomycin C follow 72 hour later single dose mitoxantrone patient acute myelogenous leukemia GM-CSF support . III . Determine toxicity profile pharmokinetics combination mitomycin C mitoxantrone . IV . Determine ability regimen induce complete response patient primary resistant refractory acute myelogenous leukemia . OUTLINE : Patients receive mitomycin C IV bolus day 1 treatment . Patients receive mitoxantrone begin day 4 . One patient enter first second dose level . Dose escalation mitoxantrone continue absence toxicity . If patient experience toxicity level 1 2 , 2 additional patient enter tier . Three patient enter subsequent tier . At tier , toxicity observe , escalation continue . If 1 3 patient experience toxicity , additional 3 patient enrol dose . If none additional patient experience toxicity , escalation continue ; however , 1 patient toxicity , trial stop . If 2 toxicity , dose de-escalated . If 2 original 3 patient toxicity , dose de-escalated . On day 15 , patient treat sargramostim ( GM-CSF ) intravenously 4 hour bone marrow free residual leukemia ; GM-CSF treatment continue ANC great 1,500/mm3 3 consecutive day . PROJECTED ACCRUAL : For pilot study mitomycin C modulation multidrug resistance protein , 12 patient accrue . For phase I study mitomycin C mitoxantrone , least 17 patient enter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelogenous leukemia , either de novo secondary ( evolve myelodysplastic syndrome , myeloproliferative syndrome , previous treatment malignancy leukemia ) OR Refractory anemia excess blast transformation Patient least 60 year old least one follow true : Failed one induction attempt First great relapse OR Patient 1859 year old without acceptable allogeneic donor autologous marrow transplant least one follow true : Failed 2 separate induction attempt , Second great relapse , Resistant relapse , Relapsed post transplant Prior treatment anthracyclines mitoxantrone require Cumulative daunorubicin dose le 400/m2 required PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70 % 100 % ( 50 % hospitalize ) Hematopoietic : Not specify Hepatic : Total direct bilirubin great 2.0 mg/dL SGOT SGPT great 3 x normal Alkaline phosphatase great 3 x normal No active hepatitis Renal : Not specify Cardiovascular : No myocardial infarction within last 6 month No congestive heart failure Ejection fraction great 50 % ( measure MUGA 2D Echo ) Pulmonary : No severe chronic obstructive pulmonary disease Other : No active infection antimicrobiologically stabilize infection Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>